Imaging CRF X NOP Interactions in Alcohol Use Disorder
ConditionAlcohol Use Disorder
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorRajesh Narendran
About this trial
This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.
Eligibility criteria
Qualifiers
Males or females between 18 and 55 years old
fulfill DSM-5 criteria for moderate or severe ( > or = 4 criteria) alcohol use disorder
fulfill both NIAAA heavy drinking91 (consuming for males > or = 5 drinks on any day; for females > or = 4 drinks on any day) and WHO high-risk/very high-risk drinking level criteria66 (for males > or = 30 drinks/week; for females > or = 20 drinks/week) in the past four weeks prior to enrollment
No lifetime DSM-5 psychiatric disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, or developmental disorders.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Baseline [C-11]NOP-1A PET scan
- Hydrocortisone
- Post-hydrocortisone [C-11]NOP-1A PET scan
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
Rajesh Narendran
Lead sponsor
University of Pittsburgh
Sponsor institution
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov